GenMark Diagnostics (GNMK) 8-K Revenues Grow 91% and Placements Increase by 20 to 102

EXHIBIT 99.1

GenMark Diagnostics Reports

First Quarter 2011 Results

Revenues Grow 91% and Placements Increase by 20 to 102

CARLSBAD, Calif., May 9, 2011 (BUSINESS WIRE) —GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported financial results for the first quarter ended March 31, 2011.

Revenues and net loss for the three months ended March 31, 2011 were $764,000 and $0.56 per share compared with $399,000 and $0.68 per share during the first quarter of 2010. The 91% increase in revenue reflects an increase in the number of systems in the field, growth in the Company’s test menu and increased volumes of tests sold. Reagent revenues grew 114% year over year to $621,000, while instrument and other revenues grew 31%. The Company placed 20 analyzers during the quarter.

Gross margin was a loss of $879,000, reflecting the manufacturing overhead spend due to duplicative manufacturing facilities. During the quarter the Company ceased manufacturing in its Pasadena, CA facility and is consolidating manufacturing in its Carlsbad, CA facility. The Company expects that the transition will be completed during the second quarter of 2011.

Operating expenses increased $1.1 million to $5.8 million during the first quarter of 2011, driven primarily by research and development spending as well as additional quality and regulatory costs associated with certifying the Carlsbad, CA manufacturing facility. Other operating expenses were approximately unchanged from the same quarter in 2010.

The Company ended the first quarter with $17.1 million in cash compared with $18.3 million at year-end, having used $3.1 million in cash flow from operations during the first quarter of 2011 compared with $5.0 million in the first quarter of 2010. The Company collected a $1.6 million Therapeutic Tax Credit in the period, which had been recorded in other assets at year end. Depreciation and amortization was $289,000 and capital expenditures were $346,000. The Company drew $2 million on its loan facility.

“The first quarter of 2011 marks a milestone in the evolution of GenMark,” commented Christopher Gleeson, GenMark’s Chairman and CEO. “With the addition of CEO, Hany Massarany and CFO, Paul Ross, we now have a complete and highly capable management team in place. In addition, our manufacturing is now consolidated into one facility, and customer interest in our products is growing at an accelerated pace. As such, our operational focus is on execution, as we manage the high level of growth we expect to experience in the near and long term,” Gleeson further stated,

INVESTOR CONFERENCE CALL

1

GenMark will hold a conference call to discuss first quarter 2011 results and the outlook for the current year at 4:00PM EST today. The conference call and webcast can be accessed live through the company’s website under the Investor Relations section. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number “64581484” approximately five minutes prior to the start time.

ABOUT GENMARK

GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark’s XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed five diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.

SAFE HARBOR STATEMENT

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding continued growth in sales of our diagnostic tests, the expansion of our diagnostic test menu, and the continued development of our technology, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

SOURCE: GenMark Diagnostics, Inc.

GenMark Diagnostics, Inc.

Paul Ross

Chief Financial Officer

760-448-4318

2

GENMARK DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	As of March 31, 2011			As of December 31, 2010
Current assets
Cash and cash equivalents	$	17,054,095		$	18,329,079
Accounts receivable, net		762,272			677,648
Inventories, net		871,033			896,809
Other current assets		382,194			2,193,160
Total current assets		19,069,594			22,096,696
Property and equipment, net		2,762,362			2,702,478
Intangible assets, net		68,042			70,980
Other long-term assets		55,355			55,355
Total assets	$	21,955,353		$	24,925,509
Current liabilities
Accounts payable	$	1,651,985		$	823,242
Accrued compensation		1,019,545			1,171,989
Other current liabilities		1,761,011			1,249,928
Total current liabilities		4,432,541			3,245,159
Long-term liabilities
Loan Payable		2,000,000			—
Other non-current liabilities		622,644			612,932
Total liabilities	$	7,055,185		$	3,858,091
Stockholders’ equity
Common stock, $.0001 par value; 100,000,000 authorized; 11,738,233 and 11,723,512 issued and outstanding as of March 31, 2011 and December 31, 2010, respectively		1,172			1,172
Preferred stock, $0.0001 par value; 5,000,000 authorized, none issued		—			—
Additional paid-in capital		166,483,672			166,009,084
Accumulated deficit		(151,134,719	)		(144,492,881	)
Accumulated other comprehensive loss		(449,957	)		(449,957	)
Total stockholders’ equity		14,900,168			21,067,418
Total liabilities and stockholders’ equity	$	21,955,353		$	24,925,509

3

GENMARK DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended March 31,
	2011			2010
Product Revenue	$	692,739		$	384,249
License and other revenue		71,664			15,015
Total revenue		764,403			399,264
Cost of sales		1,643,456			567,396
Gross loss		(879,053	)		(168,132	)
Operating expenses
Sales and marketing		1,130,389			1,058,285
General and administrative		2,111,336			2,167,264
Research and development		2,528,252			1,453,759
Total operating expenses		5,769,977			4,679,308
Loss from operations		(6,649,030	)		(4,847,440	)
Other income
Foreign exchange gain (loss)		11,899			(1,110	)
Interest income		6,258			4,654
Total other income		18,157			3,544
Loss before income taxes		(6,630,873	)		(4,843,896	)
Provision for income taxes		(10,968	)		(5,049	)
Net loss	$	(6,641,841	)	$	(4,848,945	)
Net loss per share, basic and diluted	$	(0.56	)	$	(0.68	)
Weighted average number of shares outstanding		11,771,014			7,113,922
Condensed consolidated statements of comprehensive loss three and three months ended March 31, 2011 and 2010
Net loss	$	(6,641,841	)	$	(4,848,945	)
Foreign currency translation adjustment		—			(34,647	)
Comprehensive loss	$	(6,641,841	)	$	(4,883,592	)

4

GENMARK DIAGNOSTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended March 31,
	2011			2010
Cash flows from operating activities:
Net loss	$	(6,641,841	)	$	(4,848,945	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		288,771			318,369
Change in allowance for doubtful accounts, net of write-offs		(47,785	)		—
Change in allowance for excess and obsolete inventory		(546	)		—
Share-based compensation		474,588			347,530
Changes in operating assets and liabilities:
Trade accounts receivable		(36,839	)		(71,316	)
Inventories		26,322			(65,138	)
Other current assets		1,810,966			(469,561	)
Accounts payable		667,559			(316,564	)
Accrued compensation		(152,444	)		279,184
Accrued and other liabilities		520,798			(155,724	)
Net cash used in operating activities		(3,090,451	)		(4,982,165	)
Investing activities:
Purchases of property and equipment		(184,533	)		(137,440	)
Net cash used in investing activities		(184,533	)		(137,440	)
Financing activities:
Proceeds from issuance of ordinary shares and common stock
Proceeds of loan payable		2,000,000			—
Proceeds from stock option exercises		—			4,734
Net cash provided by financing activities		2,000,000			4,734
Effect of foreign exchange rate changes		—			(46,935	)
Net decrease in cash and cash equivalents		(1,274,984	)		(5,114,871	)
Cash and cash equivalents at beginning of period		18,329,079			16,482,818
Cash and cash equivalents at end of period	$	17,054,095		$	11,321,012
Noncash investing and financing activities:
Reclassification of deposits on systems in other current assets		—		$	285,284
IPO costs incurred but not paid		—			1,537,192
Property and equipment costs incurred but not paid	$	161,184			—

5